Anixa Biosciences, Inc. has acquired Soleno Therapeutics, Inc. for $2.9 million. Soleno Therapeutics, Inc. is a biotechnology company deeply committed to the Prader-Willi syndrome (PWS) community and focused on making a meaningful difference in the lives of those impacted by rare diseases. A significant achievement for Soleno was the FDA approval in March 2025 of its therapy for the treatment of hyperphagia in PWS, which stands as the first and only approved treatment for this specific condition.
This acquisition represents a strategic expansion for Anixa Biosciences into the rare disease therapeutic market. By integrating Soleno Therapeutics, Anixa gains immediate access to a recently approved and commercially viable product, establishing a strong foothold in a specialized and underserved patient population. The transaction is expected to create operational synergies, combining Anixa's broader corporate infrastructure with Soleno's specialized scientific expertise and established relationships within the rare disease advocacy and patient communities.
The integration of Soleno's focused development capabilities with Anixa's resources is anticipated to accelerate future research and development initiatives within the rare disease space. This strategic alignment aims to enhance the combined entity's capacity to bring innovative therapies to market more efficiently. The acquisition underscores a shared commitment to addressing critical unmet medical needs and improving patient outcomes.
Looking forward, the combined organization is positioned to leverage Soleno's foundational work in Prader-Willi syndrome while exploring additional opportunities to expand its impact across the rare disease landscape. This integration is expected to strengthen the company's overall therapeutic portfolio and market presence, ultimately benefiting patients and their families affected by rare conditions.